<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03698526</url>
  </required_header>
  <id_info>
    <org_study_id>VRPC2018</org_study_id>
    <nct_id>NCT03698526</nct_id>
  </id_info>
  <brief_title>Virtual Reality for Symptoms Control in Palliative Care</brief_title>
  <acronym>VRPC</acronym>
  <official_title>Virtual Reality for Symptoms Control in Palliative Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Palliativnetz Muenster gGmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate how Virtual Reality (VR) can be used to control symptoms
      and improve the quality of life in palliative care. The interventional prospective case
      control study is planned to contain five phases including two control groups. The following
      describes only phase one to three.

      In the pilot phase patients get a one-time application of the VR-Technology. After that, two
      control groups will be recruited from patients with 1. mamma carcinoma and the indication of
      (neo-) adjuvant radiotherapy and 2. before a colonoscopy-treatment. Both groups receive the
      VR application before treatment (radiotherapy/colonoscopy).

      This first part proofs the application of Virtual Reality on patients in palliative care with
      the aim to control symptoms and reduce pain and anxiety.

      The clinical study hypothesis bases on the assumption that VR reduces pain and anxiety and
      may have a positive influence on their quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pilot phase:

      After the enrolment and consent of participation the patient receives a questionnaire
      consisting of different independent assessments. The visual analogue scale with values from 1
      to 10 quantifies subjective pain. A functional pain questionnaire (Pain-Out) is developed to
      assess the pain in between the last seven days, the associated limitations, the actions and
      side effects of combined pain therapy.

      To measure the generic health-related quality of life the patient is asked to answer the
      EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L).

      A Virtual Reality application is offered immediately after the questionnaire has been
      completed. Following the application of VR the patient will receive VAS and functional pain
      questionnaires again to assess the change from baseline.

      Control phase:

      The following control phase is to review the effectiveness of VR application on the basis of
      two different control groups. In a randomized setting 30 patients with mamma carcinoma
      receive an application of VR before their radiotherapy. The second control group consists of
      40 patients with an individual indication of a colonoscopy.

      Instead of pain by VAS and QoL in the pilot phase each patient receives now the Hospital
      Anxiety and Depression Scale (HADS) before and after the application. The Functional Pain
      Questionnaire remains with the control group of patients with mamma carcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">December 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain by VAS</measure>
    <time_frame>peri-interventional</time_frame>
    <description>Pain by VAS (visual analogue scale), Pain is indicated on a 100mm visual scale, the patient can report no pain (0 mm) to maximum pain (100mm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospital Anxiety and Depression Scale</measure>
    <time_frame>peri-interventional</time_frame>
    <description>Hospital Anxiety and Depression Scale, Questionnaire to indicate anxiety and depression, 14 questions (7 depression, 7 anxiety) with 4 possibilities to answer, validated questionnaire according to Zigmond et al. (Zigmond, A. S. &amp; Snaith, R. P. The hospital anxiety and depression scale. Acta psychiatrica Scandinavica 67, 361-370 (1983))</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional pain by Pain-Out-Questionnaire</measure>
    <time_frame>peri-interventional</time_frame>
    <description>Functional pain by Pain-Out-Questionnaire, Questionnaire in which the patient can indicate pain according to functionality (physical activity, sleeping, breathing) and feeling associated to pain (helplessness, nausea, drowsiness, Pruritus, diszziness), Scales from 0 (no symptom) to 10 (intense).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life by EQ-5D-5L</measure>
    <time_frame>peri-interventional</time_frame>
    <description>Quality of life by EQ-5D-5L, 5 Items Questionnaire and Scale from 0 (worst health status) to 100 (perfect health status), indicated by the patients, validated questionnaire according to Hinz et al. (Hinz, A., Kohlmann, T., Stobel-Richter, Y., Zenger, M. &amp; Brahler, E. The quality of life questionnaire EQ-5D-5L: psychometric properties and normative values for the general German population. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 23, 443-447, doi:10.1007/s11136-013-0498-2 (2014).)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Palliative Care</condition>
  <condition>Virtual Reality</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Palliative care I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Palliative care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with mamma carcinoma and (neo-) adjuvant radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients before colonoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Samsung Gear VR, Galaxy S8, Applied VR App</intervention_name>
    <description>Virtual Reality Experience</description>
    <arm_group_label>Control II</arm_group_label>
    <arm_group_label>Control III</arm_group_label>
    <arm_group_label>Palliative care I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minimum age of 18 years

          -  Patient understands information for participation

          -  Patients are able to give informed written consent

          -  (Informed written) consent prior inclusion in study

          -  study arm I: Indication for palliative care due to any advanced life-limiting and
             progressive diseases

          -  control II: Patients with mamma carcinoma and (neo-) adjuvant radiotherapy

          -  control III: Patients before colonoscopy

        Exclusion Criteria:

          -  Epileptic seizures in medical history

          -  Patients with claustrophobia

          -  Patients with tendency to vertigo and motion sickness

          -  Age under 18 years

          -  No informed written consent

          -  Inability to understand information for participation, language difficulties (foreign
             nationals), hardness of hearing

          -  Blindness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp Lenz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut of Palliative Care, University Hospital of Muenster</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philipp Lenz, MD</last_name>
    <phone>+4915254957580</phone>
    <email>Lenz.Philipp@ukmuenster.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Renate Schmidt, MD</last_name>
    <phone>+492518346135</phone>
    <email>Renate.Schmidt@ukmuenster.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Palliativnetz Muenster gGmbH</name>
      <address>
        <city>Muenster</city>
        <state>North Rhine-Westphalia</state>
        <zip>48161</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. med. Ulrike Hofmeister, MD</last_name>
      <phone>+49 (0)251 1625662</phone>
      <email>info@palliativnetz-muenster.de</email>
    </contact>
    <investigator>
      <last_name>Dr. med. Ulrike Hofmeister, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Muenster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PD Dr. me.d Philipp Lenz, MD</last_name>
      <phone>0049/152/54957580</phone>
      <email>Lenz.Philipp@ukmuenster.de</email>
    </contact>
    <investigator>
      <last_name>PD Dr. med. Philipp Lenz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miriam Günther</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage. 2007 Jul;34(1):94-104. Epub 2007 May 23. Review.</citation>
    <PMID>17509812</PMID>
  </reference>
  <reference>
    <citation>Gold JI, Mahrer NE. Is Virtual Reality Ready for Prime Time in the Medical Space? A Randomized Control Trial of Pediatric Virtual Reality for Acute Procedural Pain Management. J Pediatr Psychol. 2018 Apr 1;43(3):266-275. doi: 10.1093/jpepsy/jsx129.</citation>
    <PMID>29053848</PMID>
  </reference>
  <reference>
    <citation>Mosadeghi S, Reid MW, Martinez B, Rosen BT, Spiegel BM. Feasibility of an Immersive Virtual Reality Intervention for Hospitalized Patients: An Observational Cohort Study. JMIR Ment Health. 2016 Jun 27;3(2):e28. doi: 10.2196/mental.5801.</citation>
    <PMID>27349654</PMID>
  </reference>
  <reference>
    <citation>Mahrer NE, Gold JI. The use of virtual reality for pain control: a review. Curr Pain Headache Rep. 2009 Apr;13(2):100-9. Review.</citation>
    <PMID>19272275</PMID>
  </reference>
  <reference>
    <citation>Hoffman HG, Patterson DR, Carrougher GJ, Sharar SR. Effectiveness of virtual reality-based pain control with multiple treatments. Clin J Pain. 2001 Sep;17(3):229-35.</citation>
    <PMID>11587113</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>October 4, 2018</study_first_submitted>
  <study_first_submitted_qc>October 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>October 8, 2018</last_update_submitted>
  <last_update_submitted_qc>October 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

